Mandell Lionel A, Zhanel George G, Rotstein Coleman, Muscedere John, Loeb Mark, Johnstone Jennie
Department of Medicine, McMaster University, Hamilton, Canada.
Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.
Open Forum Infect Dis. 2022 Feb 4;9(3):ofac043. doi: 10.1093/ofid/ofac043. eCollection 2022 Mar.
Dealing with coronavirus disease 2019 (COVID-19) has been a monumental test of medical skills and resources worldwide. The management of community-acquired pneumonia (CAP) can at times be difficult, but treating CAP in the setting of COVID-19 can be particularly trying and confusing and raises a number of challenging questions relating to etiology, diagnosis, and treatment. This article is based on the authors' experiences and presents an overview of how CAP during COVID-19 is handled in Canada. We touch on the issues of microbial etiology in patients with CAP in the setting of COVID-19 as well as diagnostic, site of care, and treatment approaches. Published guidelines are the basis of management of CAP and are discussed in the context of Canadian data. We also outline the usual treatment approaches to COVID-19, particularly in patients who have been hospitalized.
应对2019冠状病毒病（COVID-19）是对全球医疗技能和资源的巨大考验。社区获得性肺炎（CAP）的管理有时可能很困难，但在COVID-19背景下治疗CAP可能格外棘手且令人困惑，还引发了一些与病因、诊断和治疗相关的具有挑战性的问题。本文基于作者的经验，概述了加拿大如何处理COVID-19期间的CAP。我们探讨了COVID-19背景下CAP患者的微生物病因问题以及诊断、护理地点和治疗方法。已发布的指南是CAP管理的基础，并结合加拿大的数据进行了讨论。我们还概述了COVID-19的常用治疗方法，特别是在住院患者中。
